1. Introduction {#s0005}
===============

Liver is the main detoxifying organ in the body. However, continuous exposure to certain chemotherapeutic agents, drugs, environmental toxins, viral infections or bacterial invasion can trigger liver injury and eventually lead to various liver diseases ([@b0300]). Susceptibility of the liver to injury by such agents is much higher than any other organ because of its central role in metabolism as well as its ability to concentrate and biotransform xenobiotics ([@b0170]).

Acetaminophen is an over-the-counter drug commonly used for its analgesic and antipyretic properties. Although considered a safe drug, it is the most frequent cause of severe liver failure in the world, having a mortality rate of about 90% ([@b0365]). In therapeutic levels, most of the administered dose is normally metabolized via phase II reactions and excreted as glucuronide and sulfate conjugates, while only a small portion is metabolized via phase I pathway to yield the highly toxic intermediate N-acetyl-*p*-benzoquinoneimine (NAPQI), which is normally detoxified by interaction with cellular glutathione (GSH). When GSH becomes depleted by the overproduction of NAPQI caused by saturation of the conjugation pathways at high doses, NAPQI binds to cellular macromolecules, leading to oxidative stress, cellular necrosis and finally cell death ([@b0095]).

N-acetylcysteine (NAC) is a thiol containing antioxidant which acts as a direct scavenger of free radicals and a precursor for GSH biosynthesis ([@b0310]). It can inhibit the induction of pro-inflammatory cytokines and can also block the tumor necrosis factor-α (TNF-α)-induced apoptotic cell death ([@b0290]). It is old known as the standard antidote of acetaminophen poisoning ([@b0065]).

Amlodipine is a third generation dihydropyridine-type calcium channel blocker commonly used for the treatment of hypertension. Calcium channel blockers were reported to possess hepatoprotective activities in previous studies ([@b0145]) based on the mechanistic role of calcium deregulation in the progression of hepatotoxicity ([@b0155]). In addition, the antioxidant activity of amlodipine was reported. This was attributed to its physicochemical properties where its high lipophilicity and chemical structure could facilitate proton-donating and resonance-stabilization mechanisms that quench free radicals ([@b0210]). The anti-inflammatory potential of amlodipine was also reported ([@b0360]).

Lisinopril is a lipophilic non-sulfhydryl angiotensin converting enzyme (ACE) inhibitor reported to have the ability to enhance endogenous antioxidant enzyme activities ([@b0320]). Inhibition of the rennin-angiotensin-aldosterone system may have beneficial effects on oxidative injury as angiotensin II was recently reported to cause mitochondrial oxidative injury ([@b0185]). Additionally, lisinopril was reported to have anti-inflammatory effects via suppression of the pro-inflammatory cytokines such as TNF-α production ([@b0230]).

The prototypical xanthine oxidase inhibitor allopurinol has been applied in different models of tissue injury, based on its reported ability to inhibit the production of reactive oxygen species (ROS), and the release of inflammatory mediators such as TNF-α ([@b0265], [@b0260]).

Based on the aforementioned background, the present study aims to investigate the possible protective effects of three agents acting through different mechanisms, namely amlodipine as a calcium channel blocker, lisinopril as an ACE inhibitor, and allopurinol as a xanthine oxidase inhibitor, on acetaminophen-induced hepatotoxicity in experimental rats, using NAC as a reference standard agent, aiming also to declare the role of calcium channels, ACE enzyme and xanthine oxidase enzyme in the pathogenesis of acetaminophen-induced hepatotoxicity.

2. Materials and methods {#s0010}
========================

2.1. Chemicals and diagnostic kits {#s0015}
----------------------------------

N-acetylcysteine powder was obtained as a kind gift from SEDICO Pharmaceutical Company, Egypt. Amlodipine was obtained as a kind gift from Pfizer Pharmaceutical Company, Egypt. Lisinopril was obtained as a kind gift from AstraZeneca Pharmaceutical Company, Egypt. Allopurinol was obtained as a kind gift from GlaxoSmithKline pharmaceutical company, Egypt. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) reagent kits were purchased from Spinreact (Spain). 1,1-3,3-tetramethoxypropane, 5,5′-Dithiobis-2-nitrobenzoicacid (DTNB), GSH powder, Horseradish peroxidase, N-(1-Naphthyl) ethylenediamine dihydrochloride, *o*-dianisidine hydrochloride, thiobarbituric acid (TBA), malondialdehyde (MDA), Tris-hydroxymethyl-amino methane, hexadecyltrimethylammonium bromide (HTAB) and sulfanilamide were purchased from Sigma--Aldrich (USA). Vanadium chloride was obtained from Acros (Belgium). All other chemicals used were of analytical grade.

2.2. Animals {#s0020}
------------

Adult male Wistar rats, purchased from the Modern Veterinary Office for Laboratory Animals, Cairo, Egypt, were fed with standard laboratory rat diet (Modern Veterinary Office) and water *ad libitum* until reaching weights of 180--200 g. Animals were housed in a room kept at 22--25 °C with 12-h light/12-h dark cycles, in individual stainless steel wire-bottomed cages having an upper water supply to avoid coprophagy. All animal housing and handling were conducted in compliance with the Beni-Sueif University guidelines and in accordance with the research protocols established by the Animal Care Committee of the National Research Center (Cairo, Egypt) which followed the recommendations of the National Institutes of Health Guide for Care and Use of Laboratory Animals (Publication No. 85-23, revised 1985).

2.3. Experimental design {#s0025}
------------------------

Rats were distributed into 6 groups, each of 6--8 rats, namely a normal control group, a acetaminophen hepatotoxicity control group, a standard treatment group receiving NAC, and three treatment groups receiving amlodipine, lisinopril and allopurinol, orally on a daily basis for 14 consecutive days prior to acetaminophen dose. All test agents were prepared in 1% tween 80 solution in normal saline. Drug doses were guided by the literature and adjusted through pilot trials. NAC was given in a dose of 300 mg/kg/day ([@b0010], [@b0140]), amlodipine was given in a dose of 10 mg/kg/day ([@b0070]), lisinopril was given in a dose of 20 mg/kg/day ([@b0030]), and allopurinol was given in a dose 50 mg/kg/day ([@b0035]).

2.4. Induction of hepatotoxicity {#s0030}
--------------------------------

After drug or vehicle treatment for 14 consecutive days, animals were fasted for 18 h and then received a single oral dose of acetaminophen (750 mg/kg) guided by the method described previously ([@b0250], [@b0255]) with dose adjusted through pilot trials. Animals were anaesthetized with a single dose of thiopental sodium (75 mg/kg, i.p.) 24 h after acetaminophen administration, and blood samples were collected from retro-orbital plexus using heparinized micro-capillary tubes. Rats were sacrificed thereafter by cervical dislocation to separate liver samples ([@b0160]).

2.5. Sample preparation {#s0035}
-----------------------

### 2.5.1. Serum preparation {#s0040}

After collecting blood samples in centrifuge tubes, the tubes were allowed to coagulate at room temperature and then placed in a water bath at 37 °C for 10 min. Centrifugation at 1000*g* for 20 min was performed. The clear serum was separated and used for analysis of biochemical parameters (ALT and AST).

### 2.5.2. Liver tissue preparation {#s0045}

After animals were sacrificed, the abdominal cavities were opened with livers carefully separated and washed with ice-cooled saline. Hepatic lobes were used for the preparation of liver homogenates and histopathology sections.

To prepare a 20% liver homogenate, a portion of the liver was homogenized with 5 volumes of isotonic ice-cooled normal saline using a homogenizer (Ultra-Turrax T25, made in Germany) for the estimation of hepatic thiobarbituric acid-reactive substances (TBARS), GSH, catalase (CAT) and total nitrate/nitrite (NOx; nitric oxide end products).

Another portion of the liver was homogenized with 60 volumes of ice-cooled HTAB (1%) solution in normal saline and centrifuged at 4000*g* for 15 min at 4 °C in a cooling centrifuge (model 2-16KL, Germany). The supernatant was used for the estimation of hepatic myeloperoxidase (MPO) activity.

2.6. Histopathological study {#s0050}
----------------------------

A portion of the isolated livers was immediately fixed in 10% buffered formalin solution in normal saline, dehydrated in graded concentrations of ethanol (50--100%), cleared in xylene and embedded in paraffin. Liver sections (4--5 μm) were prepared and stained with hematoxylin-eosin (H&E) dye using standard techniques for photomicroscopic observations ([@b0055]). Sections of samples were viewed and evaluated by two experienced pathologists blinded to the experiment.

2.7. Assessment of biochemical parameters {#s0055}
-----------------------------------------

Serum ALT and AST levels were assayed colorimetrically using a UV--visible double-beam spectrophotometer (model T80, made in England) according to the method described by [@b0350]. Lipid peroxidation was determined in liver homogenate as TBARS, measured as MDA according to the method of [@b0315]. Hepatic GSH was measured in the liver homogenate according to the method described by [@b0285]. Hepatic CAT activity was measured according to the method described by [@b0090]. Hepatic NOx production was assayed according to the method described by [@b0220]. Liver MPO activity was measured in liver homogenate as previously described by [@b0130].

2.8. Statistical analysis {#s0060}
-------------------------

Results were expressed as means of 6--8 rats ± standard error of the mean (SEM). All statistical analyses were performed using one way analysis of variance (ANOVA) test followed by Student--Newman--Keuls post hoc test using the statistical package for social sciences (SPSS; version 19.0) computer software program (SPSS Inc., Chicago, IL, USA) with the value of *p *\< 0.05 considered statistically significant.

3. Results {#s0065}
==========

3.1. Hepatocyte integrity markers {#s0070}
---------------------------------

Single dose acetaminophen administration significantly increased serum ALT and AST levels by about 2.6 and 3.2 folds, respectively, as compared to normal control animals. Daily oral administration of NAC, amlodipine, lisinopril or allopurinol significantly decreased serum ALT levels to about 56%, 71%, 52% and 65%, and serum AST levels to about 43%, 60%, 45% and 61%, respectively, as compared to acetaminophen control toxicity group. With NAC or lisinopril treatments, serum transaminases were restored back to normal levels ([Table 1](#t0005){ref-type="table"}). Administration of NAC, amlodipine, lisinopril or allopurinol to normal rats did not significantly affect any of the hepatocyte integrity markers (data not included).

3.2. Oxidative stress markers {#s0075}
-----------------------------

Administration of acetaminophen to rats significantly increased liver TBARS content to about 575%, significantly decreased liver GSH content to about 34%, and significantly decreased CAT activity to about 4% as compared to normal control rats. Pre-treatment of rats with NAC, amlodipine, lisinopril or allopurinol prior to acetaminophen administration significantly decreased hepatic TBARS content to about 51%, 48%, 45% and 46%, significantly increased hepatic GSH content to about 179%, 145%, 160% and 178%, and significantly increased hepatic CAT activity to about 1150%, 1025%, 1100% and 950%, respectively, as compared to acetaminophen hepatotoxicity control rats ([Table 2](#t0010){ref-type="table"}).

3.3. Inflammatory markers {#s0080}
-------------------------

Acetaminophen administration significantly increased hepatic NOx content and MPO activity to about 176% and 1005%, respectively, as compared to normal rats. Alternatively, pre-treatment of rats with NAC, amlodipine, lisinopril or allopurinol prior to acetaminophen administration significantly decreased hepatic NOx content to about 71%, 80%, 81% and 78%, and hepatic MPO activity to about 15%, 21%, 21% and 14%, respectively, as compared to acetaminophen hepatotoxicity control rats. Hepatic MPO activity was restored back to normal levels in all the treatment groups ([Table 3](#t0015){ref-type="table"}).

3.4. Histopathological study {#s0085}
----------------------------

Histopathological examination of liver sections obtained from normal control group showed normal hepatic architecture with normal central vein and radiating cords of hepatocytes. Cords of hepatocytes were separated by blood sinusoids lined with Kupffer cells as shown in [Fig. 1](#f0005){ref-type="fig"}(A). Liver sections obtained from acetaminophen hepatotoxicity control group showed irregularly dilated central vein with massive inflammatory reactions and activated Kupffer cells. Hepatocytes showed cellular degeneration and centrilobular necrosis, and were separated with dilated congested sinusoids as shown in [Fig. 1](#f0005){ref-type="fig"}(B). Animal pre-treated with NAC prior to acetaminophen dose showed that all hepatocytes were normal with slightly congested central vein. Hepatocytes were separated with slightly congested blood sinusoids with some activated Kupffer cells as shown in [Fig. 1](#f0005){ref-type="fig"}(C). Treatment of rats with amlodipine showed that all hepatocytes were normal with dilated congested central vein and activated Kupffer cells as shown in [Fig. 1](#f0005){ref-type="fig"}(D). Liver sections obtained from animals treated with lisinopril showed nearly normal architecture and normal hepatocytes with minimal congested central vein and some activated Kupffer cells as shown in [Fig. 1](#f0005){ref-type="fig"}(E). Histopathological examination of liver sections obtained from animals treated with allopurinol showed nearly normal architecture. It was observed that hepatocytes were normal with irregularly dilated congested central vein and some activated Kupffer cells as shown in [Fig. 1](#f0005){ref-type="fig"}(F).

4. Discussion {#s0090}
=============

The present investigation aims to evaluate the possible hepatoprotective effects of the calcium channel blocker amlodipine, the ACE inhibitor lisinopril, and the xanthine oxidase inhibitor allopurinol, as compared to the standard treatment NAC, on acute liver injury induced experimentally in adult male albino rats with acetaminophen.

The current investigation showed that a single oral dose administration of acetaminophen caused acute liver damage to rats as evidenced by significant increases in serum activities of ALT and AST ([Table 1](#t0005){ref-type="table"}), which are among the most sensitive indicators of hepatocyte integrity loss ([@b0045]). Liver damage was coupled with oxidative stress evidenced by significant elevation of tissue TBARS associated with significant reductions in tissue GSH and CAT levels ([Table 2](#t0010){ref-type="table"}). Inflammatory progression was also evident, reported as significant elevations of tissue NOx production and MPO activity ([Table 3](#t0015){ref-type="table"}). Biochemical findings were strongly supported by the results of histopathological examination ([Fig. 1](#f0005){ref-type="fig"}(A and B)). In agreement, previous investigations showed similar elevations of serum transaminases with comparable doses of acetaminophen in rats ([@b0040]). In addition, a similar increase in hepatic MDA content was observed by [@b0175] and [@b0085] in the same model. On the other hand, the decreases in hepatic GSH content and CAT activity are in harmony with the results reported by [@b0355], [@b0125]. Additionally, the elevations in the inflammatory biomarkers MPO and NOx are in agreement with the work of [@b0115].

Acute liver injury caused by acetaminophen is a severe condition in which metabolic homeostasis is affected. The toxicity of acetaminophen develops when its dose exceeds safe hepatic detoxification pathways such as glucuronidation and sulfation ([@b0110]) where the very reactive metabolite N-acetyl-*p*-benzoquinoneimine (NAPQI) is formed in a rate that depletes cellular GSH faster than its re-synthesis. Semiquinone radicals, obtained by one electron reduction of NAPQI, can then covalently bind to the macromolecules of cellular membrane and increase the lipid peroxidation and MDA production resulting in massive tissue damage. The damaged hepatocytes trigger a cascade of inflammatory responses leading to various degrees of liver damage which is further propagated by the migration of different extrahepatic inflammatory cells to the area of injury ([@b0080], [@b0165]).

Results of the present investigation showed that the calcium channel blocker amlodipine protected the liver against acetaminophen-induced hepatotoxicity evidenced by significant decreases in serum ALT and AST levels ([Table 1](#t0005){ref-type="table"}; [Fig. 1](#f0005){ref-type="fig"}(D)), coupled with anti-oxidant and anti-inflammatory potentials ([Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}). Although we have no reported experimental trials on amlodipine as a hepatoprotective agent against acetaminophen toxicity, amlodipine was reported to have hepatoprotective potential in other animal models of hepatotoxicity like CCl~4~-induced hepatic damage ([@b0005]).

Calcium channel blockers in general were reported to possess hepatoprotective activities in several *in vivo* and *in vitro* studies ([@b0270], [@b0145]). Hepatocytes were old known to contain several types of calcium channels ([@b0060], [@b0190]). Calcium channel blockers are of particular protective effect when hepatotoxicity is mediated by disturbed calcium homeostasis as in the case of acetaminophen-induced injury where calcium influx plays a mechanistic role in the progression of hepatotoxicity ([@b0100], [@b0155]).

The antioxidant activity of amlodipine could be related to the intrinsic structural characteristics of the dihydropyridine ring which belongs to the chain breaking group of antioxidants ([@b0075]). The dihydropyridine compounds have a reducing nature or hydrogen donor properties making them having the ability to donate protons and electrons to the lipid peroxide molecules to reduce it into a non-reactive form thereby blocking the peroxidation process ([@b0325]). Regarding the anti-inflammatory effect of amlodipine, [@b0280] reported similar decreases in MPO activity during studying the effects of chronic administration of some antihypertensive drugs on enzymatic and non-enzymatic oxidant/antioxidant parameters in rat ovarian tissue. Side by side, [@b0335] concluded that amlodipine could inhibit leucocyte adhesion and MPO release.

According to our study, pre-treatment with the ACE inhibitor lisinopril showed a hepatoprotective potential evidenced from decreased serum ALT and AST levels in acetaminophen-treated rats, supported by histopathological results ([Table 1](#t0005){ref-type="table"}; [Fig.1](#f0005){ref-type="fig"}(E)). No reported trials were evident regarding the hepatoprotective effect of lisinopril on acetaminophen-induced injury. However, [@b0240] reported anti-fibrogenic effect of lisinopril on chronic CCl~4~-induced hepatic fibrosis in rats, while [@b0230] reported hepatoprotective potential of lisinopril on ischemia--reperfusion injury in rats. In addition, these results are in agreement with [@b0345] who reported an inhibitory effect of lisinopril on endothelin-1 elevation in a partial hepatectomy model. On the other hand these results are in disagreement with [@b0120] who observed that lisinopril increased ALT level during studying the effect of lisinopril on rat liver tissues in L-NAME induced hypertension model.

The anti-oxidant activity of lisinopril, evidenced by significant corrections of oxidative stress biomarkers in the present study, came in harmony with the result of [@b0340] who reported a decreased level of MDA by lisinopril in the hippocampus of rats with L-NAME-induced hypertension. More recently, [@b0180] reported antioxidant potential for lisinopril represented as attenuation of oxidative stress in rostral ventrolateral medulla in hypertensive rats. The anti-oxidant potential of lisinopril may be related to its ability to stimulate the antioxidant defense components like CAT activity and GSH stores evident in this study. In agreement, [@b0245] reported that lisinopril increased CAT activity and attenuated renal oxidative injury in L-NAME-induced hypertension in rats, while [@b0225] demonstrated that lisinopril increased GSH level in ischemic cardiac toxicity. It should be mentioned that lisinopril is a non-thiol-containing ACE inhibitor, which indicates that lisinopril antioxidant effect, unlike thiol-containing ACE inhibitors such as captopril, is independent to thiol moiety ([@b0305]).

In the present investigation, lisinopril also showed a potent anti-inflammatory effect evidenced by decreased hepatic NOx production and MPO activity. In agreement, [@b0345] observed significant decreases in NO and ONOO^−^ levels in the liver tissue by lisinopril in a partial hepatectomy model. In addition, [@b0295] reported that lisinopril significantly decreased cardiac inducible nitric oxide synthase (iNOS) mRNA expression. Lisinopril was reported to have immune-modulatory functions as it could suppress IL-12 which is a cytokine produced primarily by monocytes and macrophages with an essential role in cell-mediated immunity ([@b0015]).

Results of the present investigation also revealed that allopurinol could protect rat liver against acetaminophen-induced injury, evidenced by decreased serum ALT and AST levels, supported by histopathological improvements ([Table 1](#t0005){ref-type="table"}; [Fig. 1](#f0005){ref-type="fig"}(F)). In agreement, [@b0105] showed similar results in thioacetamide-induced acute liver failure. Moreover, [@b0150] reported a similar hepatoprotective potential for another xanthine oxidase inhibitor, febuxostat, against acetaminophen and uric acid-induced hepatitis.

The current investigation demonstrated that allopurinol has a potent antioxidant activity which was evidenced by modulation of oxidative stress biomarkers. It was found that allopurinol significantly increased hepatic GSH content and CAT activity. These findings confirmed the result of [@b0025] who reported a similar increase in GSH in a model of azathioprine-induced cytotoxicity, [@b0275] who studied a protective effect for allopurinol on hypoxanthine-induced oxidative stress in rat kidney, and [@b0020] who studied the beneficial effects of allopurinol against cyclosporine-induced hepatotoxicity.

In addition, the present work showed that allopurinol had anti-inflammatory activity proved by significant decreases in hepatic MPO activity and NOx production. These results came in agreement with the work of [@b0050] who reported that allopurinol decreased MPO activity and exerted a neuroprotective effect against cerebral ischemia reperfusion injury in diabetic rats. In addition, [@b0200] found that allopurinol decreased MPO activity in intestinal ischemic injury in rats. A further support for this idea was provided by [@b0195] who reported a similar decrease in NO~X~ production during studying the role of allopurinol on oxidative stress in experimental hyperthyroidism.

Allopurinol competitively inhibits the action of xanthine oxidoreductase enzyme responsible for the generation of massive amounts of reactive oxygen intermediates. Allopurinol could therefore prevent liver injury by the inhibition of free radical formation ([@b0205], [@b0035]). Another possible explanation for the beneficial effects of allopurinol is the preservation of hypoxanthine through the blockade of xanthine oxidase, which can act as a substrate to form ATP ([@b0215], [@b0135]). Recently, [@b0330] reported that the beneficial effect of allopurinol on acetaminophen-induced liver injury may be attributed to the effect of the former on aldehyde oxidase-mediated liver preconditioning.

Allopurinol was also reported to have immunomodulatory properties evidenced as suppression of nuclear expression of nuclear factor kappa B (NF-κB) as well as attenuation of the expression of inflammatory adhesion molecules in murine models ([@b0235], [@b0035]).

Results of the present investigation suggest three good hepatoprotective strategies, namely calcium channel blockade, ACE inhibition and xanthine oxidase inhibition, through amlodipine, lisinopril and allopurinol, respectively. Hepatoprotective potentials are mostly through anti-oxidant, anti-inflammatory, immunomodulatory and calcium regulatory activities. This study may give a good guide to acetaminophen hepatotoxic mechanisms, which may give a helpful key for further trials on other drugs with similar mechanisms against such injury.

Peer review under responsibility of King Saud University.

![(A) A photomicrograph of liver section obtained from control rats (H&E × 40). The section shows normal hepatic architecture with central vein (red arrow) and radiating cords of hepatocytes (star). Cords of hepatocytes are separated by blood sinusoids (blue arrow) lined with Kupffer cells (white arrow). (B) A photomicrograph of liver section obtained from acetaminophen hepatotoxicity control rats (H&E × 40). The section shows irregularly dilated central vein (red arrow) with massive inflammatory reactions and activated Kupffer cells (white arrow). Hepatocytes are showing cellular degeneration and centrilobular necrosis (yellow arrow). Hepatocytes are separated with dilated congested sinusoids (blue arrow). (C) A photomicrograph of liver section obtained from rats intoxicated with acetaminophen and pre-treated with N-acetylcysteine (H&E × 40). The section shows that all hepatocytes are normal with slightly congested central vein (red arrow). Hepatocytes are separated with slightly congested blood sinusoids (blue arrow) with some activated Kupffer cells (white arrow). (D) A photomicrograph of liver section obtained from rats intoxicated with acetaminophen and pre-treated with amlodipine (H&E × 40). The section shows that all hepatocytes (star) are normal with dilated congested central vein (red arrow) and activated Kupffer cells (white arrow). (E) A photomicrograph of liver section obtained from rats intoxicated with acetaminophen and pre-treated with lisinopril (H&E × 40). The section shows nearly normal architecture and normal hepatocytes (star) with minimal congested central vein (red arrow) and some activated Kupffer cells (white arrow). (F) A photomicrograph of liver section obtained from rats intoxicated with acetaminophen and pre-treated with allopurinol (H&E × 40). The section shows normal architecture and normal hepatocytes (star) with irregularly dilated congested central vein (red arrow) and some activated Kupffer cells (white arrow).](gr1){#f0005}

###### 

Effect of NAC, amlodipine, lisinopril or allopurinol administration on markers of liver injury.

  Parameters        Control group[A](#tblfn1){ref-type="table-fn"}   Acetaminophen group[B](#tblfn2){ref-type="table-fn"}   NAC treatment group[C](#tblfn3){ref-type="table-fn"}   Amlodipine treatment group[D](#tblfn4){ref-type="table-fn"}                      Lisinopril treatment group[E](#tblfn5){ref-type="table-fn"}   Allopurinol treatment group[F](#tblfn6){ref-type="table-fn"}
  ----------------- ------------------------------------------------ ------------------------------------------------------ ------------------------------------------------------ -------------------------------------------------------------------------------- ------------------------------------------------------------- ---------------------------------------------------------------------------------
  Serum ALT (U/L)   45.3 ± 2.68                                      117.8 ± 18.53[a](#tblfn7){ref-type="table-fn"}         65.7 ± 5.08[b](#tblfn8){ref-type="table-fn"}           84.1 ± 4.39[a](#tblfn7){ref-type="table-fn"}[b](#tblfn8){ref-type="table-fn"}    61.8 ± 9.23[b](#tblfn8){ref-type="table-fn"}                  76.8 ± 5.09[b](#tblfn8){ref-type="table-fn"}
  Serum AST (U/L)   155.3 ± 9.98                                     503.0 ± 76.78[a](#tblfn7){ref-type="table-fn"}         218.0 ± 3.69[b](#tblfn8){ref-type="table-fn"}          303.0 ± 7.63[a](#tblfn7){ref-type="table-fn"}[b](#tblfn8){ref-type="table-fn"}   225.5 ± 21.45[b](#tblfn8){ref-type="table-fn"}                307.8 ± 10.79[a](#tblfn7){ref-type="table-fn"}[b](#tblfn8){ref-type="table-fn"}

Data are expressed as mean of 6--8 rats ± SEM. Multiple comparisons were done using one-way ANOVA test followed by Student--Newman--Keuls as post hoc test.

ALT: Alanine transaminase, ANOVA: Analysis of variance, AST: Aspartate transaminase, NAC: N-acetylcysteine, SEM: Standard error of the mean.

Control group receiving only vehicles.

Acetaminophen group, subjected to a single oral dose of acetaminophen (750 mg/kg).

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where NAC was given in a dose of 300 mg/kg/day.

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where amlodipine was given in a dose of 10 mg/kg/day.

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where lisinopril was given in a dose of 20 mg/kg/day.

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where allopurinol was given in a dose of 50 mg/kg/day.

Significantly different from control group.

Significantly different from acetaminophen group at *p *\< 0.05.

###### 

Effect of NAC, amlodipine, lisinopril or allopurinol administration on markers of oxidative stress.

  Parameters                   Control group[A](#tblfn9){ref-type="table-fn"}   Acetaminophen group[B](#tblfn10){ref-type="table-fn"}   NAC treatment group[C](#tblfn11){ref-type="table-fn"}                                Amlodipine treatment group[D](#tblfn12){ref-type="table-fn"}                                                         Lisinopril treatment group[E](#tblfn13){ref-type="table-fn"}                         Allopurinol treatment group[F](#tblfn14){ref-type="table-fn"}
  ---------------------------- ------------------------------------------------ ------------------------------------------------------- ------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------
  Hepatic TBARS (nmol/g)       24.2 ± 3.20                                      139.1 ± 7.21[a](#tblfn15){ref-type="table-fn"}          70.6 ± 5.91[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}      67.3 ± 6.85[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}                                      61.9 ± 4.15[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}      63.5 ± 5.68[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}
  Hepatic GSH (μmol/g)         394.6 ± 24.47                                    135.2 ± 1.98[a](#tblfn15){ref-type="table-fn"}          242.0 ± 9.54[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}     195.5 ± 5.58[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}[c](#tblfn17){ref-type="table-fn"}   215.8 ± 2.83[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}     240.5 ± 7.43[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}
  Hepatic CAT (U/mg protein)   0.091 ± 0.0078                                   0.004 ± 0.0017[a](#tblfn15){ref-type="table-fn"}        0.046 ± 0.0177[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}   0.041 ± 0.0057[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}                                   0.044 ± 0.0076[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}   0.038 ± 0.0036[a](#tblfn15){ref-type="table-fn"}[b](#tblfn16){ref-type="table-fn"}

Data are expressed as mean of 6--8 rats ± SEM. Multiple comparisons were done using one-way ANOVA test followed by Student--Newman--Keuls as post hoc test.

ANOVA: Analysis of variance, CAT: Catalase, GSH: Glutathione reduced, NAC: N-acetylcysteine, SEM: Standard error of the mean, TBARS: Thiobarbituric acid reactive substances.

Control group receiving only vehicles.

Acetaminophen group, subjected to a single oral dose of acetaminophen (750 mg/kg).

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where NAC was given in a dose of 300 mg/kg/day.

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where amlodipine was given in a dose of 10 mg/kg/day.

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where lisinopril was given in a dose of 20 mg/kg/day.

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where allopurinol was given in a dose of 50 mg/kg/day.

Significantly different from control group.

Significantly different from acetaminophen group.

Significantly different from standard treatment (NAC) group at *p *\< 0.05.

###### 

Effect of NAC, amlodipine, lisinopril or allopurinol administration on markers of inflammation.

  Parameters             Control group[A](#tblfn18){ref-type="table-fn"}   Acetaminophen group[B](#tblfn19){ref-type="table-fn"}   NAC treatment group[C](#tblfn20){ref-type="table-fn"}                              Amlodipine treatment group[D](#tblfn21){ref-type="table-fn"}                       Lisinopril treatment group[E](#tblfn22){ref-type="table-fn"}                       Allopurinol treatment group[F](#tblfn23){ref-type="table-fn"}
  ---------------------- ------------------------------------------------- ------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ---------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  Hepatic NOx (nmol/g)   123.5 ± 5.99                                      216.7 ± 7.05[a](#tblfn24){ref-type="table-fn"}          153.7 ± 9.43[a](#tblfn24){ref-type="table-fn"}[b](#tblfn25){ref-type="table-fn"}   174.4 ± 2.51[a](#tblfn24){ref-type="table-fn"}[b](#tblfn25){ref-type="table-fn"}   175.9 ± 3.63[a](#tblfn24){ref-type="table-fn"}[b](#tblfn25){ref-type="table-fn"}   168.8 ± 3.25[a](#tblfn24){ref-type="table-fn"}[b](#tblfn25){ref-type="table-fn"}
  Hepatic MPO (U/g)      0.380 ± 0.0574                                    3.820 ± 0.3739[a](#tblfn24){ref-type="table-fn"}        0.574 ± 0.0779[b](#tblfn25){ref-type="table-fn"}                                   0.819 ± 0.1429[b](#tblfn25){ref-type="table-fn"}                                   0.790 ± 0.0929[b](#tblfn25){ref-type="table-fn"}                                   0.547 ± 0.1240[b](#tblfn25){ref-type="table-fn"}

Data are expressed as mean of 6--8 rats ± SEM. Multiple comparisons were done using one-way ANOVA test followed by Student--Newman-Keuls as post hoc test.

ANOVA: Analysis of variance, MPO: Myeloperoxidase, NAC: N-acetylcysteine, NOx: Total nitrate/nitrite, SEM: Standard error of the mean.

Control group receiving only vehicles.

Acetaminophen group, subjected to a single oral dose of acetaminophen (750 mg/kg).

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where NAC was given in a dose of 300 mg/kg/day.

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where amlodipine was given in a dose of 10 mg/kg/day.

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where lisinopril was given in a dose of 20 mg/kg/day.

Test agents were given orally on a daily basis for 14 consecutive days prior to acetaminophen dose, where allopurinol was given in a dose of 50 mg/kg/day.

Significantly different from control group.

Significantly different from acetaminophen group at *p *\< 0.05.

[^1]: Cell: +20 1227468223.

[^2]: Cell: +20 235616149.
